Literature DB >> 27701375

Intraoperative radiotherapy in gastric and esophageal cancer: meta-analysis of long-term outcomes and complications.

Peng Gao1, Chengche Tsai1, Yuchong Yang1, Yingying Xu2, Changwang Zhang1, Cong Zhang1, Longyi Wang1, Hongpeng Liu1, Zhenning Wang3.   

Abstract

INTRODUCTION: The treatment effects of intraoperative radiotherapy (IORT) for gastric and esophageal cancer remain uncertain. We therefore performed meta-analyses to investigate whether IORT was associated with more favorable oncologic outcomes when compared to non-IORT for patients who have gastric or esophageal cancer. EVIDENCE ACQUISITION: PubMed, Embase, and the references of relevant studies were systematically searched up to March 2016. Outcomes were analyzed with fixed-effect or random-effect models, and the meta-analysis was completed with odds ratio (OR), hazards ratio (HR), and 95% confidence intervals (CI) as effect values. EVIDENCE SYNTHESIS: Eleven studies were included, nine for gastric cancer and two for esophageal cancer. The studies included 1581 patients, 570 in the IORT group and 1011 in the control group. There was no significant difference in overall survival (OS) between the IORT group and control group (HR=0.91, 95% CI: 0.73-1.13; P=0.38). Two subgroups based on cancer type also had the similar results (gastric group: HR=0.98, 95% CI: 0.78-1.24, P=0.87; esophagus group: HR=0.63, 95% CI: 0.37-1.05, P=0.08). Besides, IORT showed favorable effects for patients with cancer in stage II and stage III and had the advantage of loco-regional control. Regarding the complications, the occurrence rate had no significant difference between the IORT group and control group (OR=1.15; 95% CI: 0.77-1.72; P=0.50).
CONCLUSIONS: According to our meta-analysis, IORT did not extend the OS in gastric cancer and esophageal cancer patients, but had a favorable effect for specific stage patients to show loco-regional control, and did not increase the risk of complications.

Entities:  

Mesh:

Year:  2016        PMID: 27701375     DOI: 10.23736/S0026-4806.16.04628-0

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  7 in total

1.  The Use of Intraoperative Radiation Therapy (IORT) in Multimodality Management of Cancer Patients: a Single Institution Experience.

Authors:  Ahmed Elashwah; Abdullah Alsuhaibani; Ali Alzahrani; Ayman Zaki Azzam; Belal Moftah; Mohammad Breakeit; Muhammad Hussain; Rana Mahmood; Shada ALramahi; Zeinab Hassan; Tarek Mahmoud Amin
Journal:  J Gastrointest Cancer       Date:  2022-03-15

2.  Clinical feasibility of combining intraoperative electron radiation therapy with minimally invasive surgery: a potential for electron-FLASH clinical development.

Authors:  Felipe Ángel Calvo Manuel; Javier Serrano; Claudio Solé; Mauricio Cambeiro; Jacobo Palma; Javier Aristu; Jose Luis Garcia-Sabrido; Miguel Angel Cuesta; Emilio Del Valle; Fernando Lapuente; Bernardino Miñana; Miguel Ángel Morcillo; Jose Manuel Asencio; Javier Pascau
Journal:  Clin Transl Oncol       Date:  2022-09-28       Impact factor: 3.340

3.  Combined Prophylactic Hyperthermic Intraperitoneal Chemotherapy and Intraoperative Radiotherapy for Localized Gastroesophageal Junction and Gastric Cancer: A Comparative Nonrandomized Study.

Authors:  Shouki Bazarbashi; Ahmed Badran; Ahmed Mostafa Gad; Ali Aljubran; Ahmed Alzahrani; Aisha Alshibani; Reem Alrakaf; Tusneem Elhassan; Abdullah Alsuhaibani; Mahmoud A Elshenawy
Journal:  Ann Surg Oncol       Date:  2022-08-30       Impact factor: 4.339

4.  Circular RNA circHECTD1 prevents Diosbulbin-B-sensitivity via miR-137/PBX3 axis in gastric cancer.

Authors:  Yizhuo Lu; Long Li; Lianghui Li; Guoyang Wu; Guoyan Liu
Journal:  Cancer Cell Int       Date:  2021-05-17       Impact factor: 5.722

5.  Osthole inhibits gastric cancer cell proliferation through regulation of PI3K/AKT.

Authors:  Xiaojun Xu; Xiaoyuan Liu; Yan Zhang
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

6.  LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis.

Authors:  Niansheng Ren; Tao Jiang; Chengbo Wang; Shilin Xie; Yanwei Xing; Daxun Piao; Tiemin Zhang; Yuekun Zhu
Journal:  Aging (Albany NY)       Date:  2020-06-09       Impact factor: 5.682

7.  The Role of Tumor Microenvironment in Chemoresistance: 3D Extracellular Matrices as Accomplices.

Authors:  Dimakatso Alice Senthebane; Tina Jonker; Arielle Rowe; Nicholas Ekow Thomford; Daniella Munro; Collet Dandara; Ambroise Wonkam; Dhirendra Govender; Bridget Calder; Nelson C Soares; Jonathan M Blackburn; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2018-09-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.